Background More than 1·5 billion people are aff ected by schistosomiasis or soil-transmitted helminthiasis. WHO's recommendations for mass drug administration (MDA) against these parasitic infections emphasise treatment of school-aged children, using separate treatment guidelines for these two helminthiases groups. We aimed to evaluate the cost-eff ectiveness of expanding integrated MDA to the entire community in four settings in Côte d'Ivoire.
Introduction
Elimination of schistosomiasis and soil-transmitted helminthiasis poses a great challenge, but is an even greater opportunity to alleviate the suff ering of the more than 1·5 billion people who are infected with the parasitic worms that give rise to these diseases. 1, 2 Discussions surrounding helminth infections, a subset of the neglected tropical diseases, have shifted from control to elimination in the past few years. 3, 4 This change has been shown in the increased international funding for mass treatment campaigns from foreign aid programmes, nongovernmental organisations, and philanthropy, in addition to expanded drug donation programmes by pharmaceutical companies. 3, 5 To achieve these ambitious aims, WHO issued a roadmap 3 for the control and elimination of neglected tropical diseases, which advocates for expansion of mass drug administration (MDA) to address the large disease burden of helminthiases, including schistosomiasis and soil-transmitted helminthiasis (caused by infection with Ascaris lumbricoides, the two hookworm species Ancylostoma duodenale and Necator americanus, and Trichuris trichiura).
Consistent with published guidelines by WHO, 6 MDA programmes provide large-scale empirical drug e630
www.lancet.com/lancetgh Vol 3 October 2015 distribution irrespective of individual infection status and have previously targeted school-aged children (aged 5-14 years) through school-based delivery schemes (appendix). This approach has been universally viewed as cost eff ective and practical, since children are believed to harbour a higher disease burden and greater disability than adults do. Additionally, schools provide an eff ective distribution platform and drugs are often donated by pharmaceutical companies for these purposes. [6] [7] [8] However, despite the eff orts of regular MDA campaigns, the disease burden of schistosomiasis and soiltransmitted helminthiasis has remained high. 9, 10 The latest WHO recommendations 6, 11 are used to guide MDA strategies, but were developed without a goal of elimination, are not based on a cost-eff ectiveness framework, and provide separate treatment recommendations for schistosomiasis and soiltransmitted helminthiasis with little guidance for the role of integrated treatment programmes. Recent work in the past two years has suggested the importance of expansion of MDA to additional age groups to overcome high reinfection rates and potentially enable elimination of these diseases. 5, 12, 13 However, the cost-eff ectiveness of expanding treatment to additional age groups is unknown.
Crucial, policy-relevant questions remain about the cost-eff ectiveness of integrated MDA programmes that might vary substantially in diff erent contexts and settings-eg, when treatment is provided to the entire community (rather than school-aged children only), whether elimination of diseases is met or not, administration of diff erent frequencies and treatment coverage, and the varying prevalence and intensities of infection in communities. To address these policyrelevant scenarios, we modelled the cost-eff ectiveness of MDA strategies for schistosomiasis and soil-transmitted helminthiasis using data from four communities in Côte d'Ivoire and compared integrated, community-wide MDA with treatment of only school-aged children, current WHO guidelines, and other MDA scenarios. 6 
Methods

Model overview
We extended the work of existing transmission models for helminth infections [13] [14] [15] to include multiple helminth infections, disability estimates, costs, and simulation of integrated treatment targeted with praziquantel for schistosomiasis and albendazole for soil-transmitted helminthiasis. By use of empirical data from four communities in Côte d'Ivoire, we simulated communities of 5000 people and projected age-specifi c prevalence and intensity of infections (ie, mean worm burden, often measured in eggs per g of faeces) over 15 years. [16] [17] [18] [19] [20] We compared annual MDA for school-aged children alone; school-aged children and preschool-aged children (aged 2-4 years); adults alone (aged ≥15 years); and the entire community, using no treatment as a base case. Each treatment strategy was applied for 15 years. Strategies were compared with treatment intervals of 3 months, 4 months, 6 months, 1 year, 2 years, 3 years, and 4 years. 6 We modelled the total disability averted and direct costs of MDA treatment programmes in four simulated communities of 5000 people in Côte d'Ivoire (A-D) to model medium-sized communities.
We defi ned direct costs in 2014 US dollars (US$) and measured total disability averted in the disability-adjusted life-year (DALY) after published sequelae and weights. 1, 8, [21] [22] [23] Cost-eff ectiveness was measured with the incremental cost-eff ectiveness ratio (ICER), defi ned as the incremental cost divided by the incremental disability averted ($ per DALY averted). We deemed treatment strategies to be highly cost eff ective if the ICER was below the per-capita
Research in context
Evidence before this study We searched PubMed for relevant articles published in English before Aug 22, 2015, using the search terms "helminth" or "schistosomiasis" together with "cost-eff ectiveness" and "treatment" restricted to the title and abstract fi elds. This search identifi ed 34 articles. Of these, ten studies reported about the cost-eff ectiveness of mass drug administration (MDA) against schistosomiasis or soil-transmitted helminthiasis alone and three studies discussed integrated treatment of schistosomiasis, soil-transmitted helminthiasis, or other diseases. However, none of these studies evaluated the cost-eff ectiveness of integrated community-wide MDA against schistosomiasis and soiltransmitted helminthiasis using the disability-adjusted life-year.
Added value of this study
Our fi ndings suggest that integrated community-wide MDA with high coverage (>75%) and sustained administration (>5 years) against schistosomiasis and soil-transmitted helminthiasis could be crucial in decreasing community disease burden and lowering reinfection. Expanded community-wide MDA was highly cost eff ective in four Côte d'Ivoire communities across a range of conditions, including when elimination could not be achieved. Increasing treatment intervals to every 6 months was also reported to be highly cost eff ective. This study goes beyond previous work to provide a rigorous multisetting cost-eff ectiveness analysis to optimise MDA against two major groups of helminthiases.
Implications of all evidence available
Recent models and our fi ndings support the need to revise global guidelines to address expansion of MDA to the entire community where these diseases are endemic, and improve guidance for integration of treatment programmes for schistosomiasis and soil-transmitted helminthiasis. Alternative or complementary interventions might also be needed to achieve elimination of these infections.
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gross domestic product of Côte d'Ivoire ($1521 in 2013). 24 Future costs and disability averted were discounted at 3% per year, and undiscounted results are also presented.
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Transmission model and assumptions
We adapted a dynamic, age-structured, and deterministic transmission model to project population-level burden of helminth infections during the 15-year simulation period. We simultaneously modelled the transmission dynamics of fi ve helminths: Schistosoma haematobium, Schistosoma mansoni, A lumbricoides, T trichiura, and hookworm. Every helminth type's lifecycle was modelled by tracking the mean worm burden in every age group. This process is driven by the production of eggs and excretion of this infectious material into the environment, uptake of infectious material through either ingestion of eggs or contact with larvae, and mortality of the worm within the host (appendix). Individuals were modelled as susceptible to reinfection immediately after treatment. On the basis of previous models and empirical observation of helminthiases distribution, prevalence of helminth infection was assumed to follow a negative binomial distribution with respect to burden of infection (worm burden or eggs per g [S haematobium is measured in eggs per 10 mL urine]). [12] [13] [14] [15] This distribution was recalculated at every time step of the model (1 month). A heterogeneous mixing model was derived to allow various extents of interaction between age groups and the environment. Reproduction number and exposure rate were calculated from primary epidemiological data specifi c to each Côte d'Ivoire community and age group, using the assumption that preschool-aged children and school-aged children contributed twice the relative amount of eggs to the environment than did adults (appendix).
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Treatment and disability model and assumptions
We modelled the treatment eff ect of MDA with praziquantel (for schistosomiasis) and albendazole (for soil-transmitted helminthiasis) on prevalence of helminth infections and DALYs. Treatment was modelled Infection intensity*
Disability weights
Schistosoma mansoni
Infection 21 All 0·005-0·02
Schistosoma haematobium
Ascaris lumbricoides
Mild abdominopelvic problems Moderate 0·0108
Symptomatic infection Heavy 0·0296
Wasting † Heavy 0·1245
Trichuris trichiura
Hookworm
Mild abdominopelvic problems Moderate to heavy 0·0108
Anaemia
Mild anaemia ‡ All 0·0041
Moderate anaemia ‡ All 0·0056
Severe anaemia ‡ All 0·1615
All infection intensities include light, moderate, and heavy infections. Table  adapted from Pullan and colleagues, 1 with permission. *Based on eggs per g in faeces (appendix). †Wasting was applied to only a subset of children harbouring a heavy infection. ‡Anaemia averted through treatment was calculated independent of intensity of infection, and modelled separately as a result of either hookworm infection or schistosomiasis. Treatment coverage in all communities 3 75%
Praziquantel and albendazole EPG reduction 27-29
Schistosoma spp 85% Hookworm 89·5%
Ascaris lumbricoides 97·5%
Trichuris trichiura 64%
Life expectancy (years) 15 
Schistosoma spp 4
Hookworm 2·5
A lumbricoides 1·5
T trichiura 1·5
Hb=haemoglobin. EPG=eggs per g of faeces (except for Schistosoma haematobium that is measured in eggs per 10 mL of urine). *Community-based delivery was assumed to be three times the cost of school-based delivery. as an instant reduction in mean worm burden, 5, 8, [12] [13] [14] 26 estimated from extent of reduction of eggs per g of faeces reported in clinical trials. [27] [28] [29] We used a treatment coverage of 75% to adhere with the WHO goal for helminthiases MDA by 2020. 3 Disability was calculated on the basis of the infection intensity of individuals within the population and updated disability weights (DALYs; table 1). 1, 8, [21] [22] [23] For soiltransmitted helminthiasis, the population was divided into four categories-no infection, light intensity, moderate intensity, and heavy intensity infection-with associated sequelae based on eggs per g of faeces, which was used as an indicator for severity of infection. Schistosomiasis was treated as binary, whereby individuals were either regarded as uninfected or infected according to reported disability weights. 21, 23 Anaemia was modelled by a calculation of the proportion of mild, moderate, and severe anaemia that resolved through treatment of hookworm infection and schistosomiasis. This calculation consisted of a mixture model methodology and documented downward shifts in haemoglobin for any individual with hookworm infection or schistosomiasis (appendix). [30] [31] [32] [33] Wasting was estimated by determining the proportion of national child wasting in Côte d'Ivoire attributable to heavy helminth infections on the basis of reported Z-score estimates of the reduction in weight for height due to heavy helminth infection. 34, 35 Polyparasitism is common in Côte d'Ivoire 36 and was modelled under the assumptions that acquisition of each infection was independent from one another, which was supported by an absence of strong or consistent correlation between infections detected from crosssectional surveys completed in Côte d'Ivoire (appendix). Disability for individuals with polyparasitism and multiple sequelae were treated as multiplicative following convention.
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Input epidemiological and cost data
For epidemiological parameters specifi c to every community and age group, we used primary agestructured data on prevalence and intensity of infection of Schistosoma and soil-transmitted helminths from cross-sectional surveys done in four separate untreated communities with diverse geography and climate within Côte d'Ivoire. [16] [17] [18] [19] [20] Prevalence and intensity of infection were adjusted for imperfect diagnostics (appendix).
Treatment costs included both drug and delivery costs, and were calculated from the perspective of fi nancial costs of a neglected tropical diseases treatment programme under the framework of a national campaign (table 2) . School-based delivery costs were applied to school-aged children, and community-based delivery costs were used for preschool-aged children and adults. These costs were estimated from the scientifi c literature and the International Drug Price Indicator Guide, and refl ected the cost of praziquantel, albendazole, and delivery costs, adjusted through the US Consumer Price Index to 2014 US dollars. We conservatively assumed that praziquantel and albendazole were not donated, and priced at $0·21 and $0·03, respectively. [6] [7] [8] 39 School-based delivery costs were estimated at $0·50, which represent the higher end of price estimations from the literature. 7, 8, [40] [41] [42] [43] [44] [45] [46] [47] [48] Estimated delivery costs from the literature included drug shipment, vehicle use, staff salaries, planning costs, technical support, and daily compensation, among other included costs. Indirect delivery costs associated with volunteer time for schoolbased delivery (eg, teachers) were not explicitly included in many of these estimations. Community treatment was assumed to have delivery costs that were three times that of school-based programmes because of the increased logistical costs of community delivery and remuneration to community health workers.
8,45,48
Although we did not scale delivery costs with the size of the treated population, we used cost estimations that were conservative and did not assume advantages from economies of scale. The composite cost for treatment was estimated to be $0·74 for school-aged children and $1·74 for community treatment to preschool-aged children and adults.
7,8,29
Statistical analysis
We did a series of one-way sensitivity analyses and a probabilistic sensitivity analysis by varying key parameters of our model across a range of feasible values. We used these data to determine the robustness of our results and the eff ect of specifi c assumptions. Our one-way sensitivity analyses assessed the eff ect of varying one parameter on the ICER value of integrated community-wide treatment compared with targeting only school-aged children. We examined the most infl uential parameters, including the school-based and community-based delivery cost, disability weight for schistosomiasis, frequency of treatment, coverage, and association between the relative contribution of infectious material into the environment between preschool-aged children, school-aged children, and adults (appendix). The authors fully support the importance of data sharing and transparency in research; full model code and data are available on request to the authors.
Role of the funding source
The funder of this study had no role in the design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Four communities in Côte d'Ivoire were surveyed between March, 1997, and September, 2010, for helminth infections. [16] [17] [18] [19] [20] The prevalence of helminth infections investigated was highly variable between age groups and the four communities (fi gure 1A, appendix). All four communities had a higher prevalence of helminth infections in adults than in school-aged children. Of the four communities, communities A and B had high burdens (>50% prevalence in school-aged children) for schistosomiasis, whereas communities C and D had a moderate burden (10-50%). Communities B, C, and D had a low burden (20-50% prevalence among schoolaged children) for soil-transmitted helminthiasis, whereas community A was deemed no risk (<20%). Following WHO guidelines for helminthiases control programmes, the four communities would have been classifi ed under three unique recommendations for MDA (fi gure 1B). Costs and disability are discounted at 3% annually. DALY=disability-adjusted life-year. ICER=incremental costeff ectiveness ratio. NA=not applicable. SAC=school-aged children (5-14 years). Pre-SAC=preschool-aged children (2-4 years). *Dominated strategy defi ned as intervention with higher ICER than more eff ective strategy. In the four simulated communities of 5000 people in Côte d'Ivoire (A-D), the total disability attributable to helminth infections, in the absence of treatment, was projected to be 3252·1 DALYs (undiscounted 4090·7 DALYs) during 15 years (table 3) . Schistosomiasis was the leading cause of disability in all four communities. Most disability resulted from Schistosoma infections (92%) and combined anaemia from hookworm and schistosomiasis (6%; appendix). Notably, T trichiura and A lumbricoides infections together accounted for only 1% of total disability.
We modelled the eff ect of changing coverage of treatment and inclusion of broader age groups (preschoolaged children and adults) on mean burden and prevalence. For most helminth species and communities, approaching elimination required substantial treatment coverage (>75% of the population), sustained administration (>5 years), and broad inclusion of age groups (communitywide treatment). By comparison, the latest WHO guidelines 6, 11 that propose annual treatment of only schoolaged children with 75% coverage resulted in a minimum decrease in prevalence and mean burden of helminths (fi gure 2). Notably, the school-aged children and adult populations in community B who had high-intensity schistosomiasis and the preschool-aged children in community C with high-intensity T trichiura needed treatment every 6 months to approach elimination of these infections (data shown in appendix).
Implementation of an integrated MDA programme with 75% coverage in school-aged children was a highly costeff ective intervention compared with giving no treatment. We projected that treatment of only school-aged children would avert 288 DALYs over 15 years at a cost of $34 122 (ICER $118 per DALY averted [table 3], varying among the communities from $87 to $141 per DALY averted). Our model suggests that coverage of the entire community would result in an additional 1443 DALYs averted at an incremental cost of $240 695 (ICER $167 per DALY averted, varying among the communities from $101 to $463 per DALY averted). Community-wide MDA was therefore highly cost eff ective by comparison with treatment of only school-aged children (table 3; appendix). Treatment of preschool-aged children and school-aged children together or adults alone was dominated by community-wide treatment, in that these alternative strategies had a higher ICER and lower overall eff ectiveness than communitywide treatment (appendix).
We also did a cost-eff ectiveness analysis independently for all of the four communities (appendix). These communities ranged from low to high disease-burden regions, and varied in Schistosoma prevalence from 11% to 63%. In all settings, community-wide treatment was highly cost eff ective compared with treatment of schoolaged children alone (appendix).
The cost-eff ectiveness of all treatment strategies was quite robust across the full range of treatment coverage ($149-277 per DALY averted from 100% to 5% coverage), suggesting that both control and elimination strategies were highly cost eff ective (fi gure 3). For three (A-C) of the four communities, community-wide administration showed improving cost-eff ectiveness as the coverage rate increased above 50%. This occurrence was only reported in the community-wide treatment strategy, and was presumably a result of approaching elimination through broad inclusion of age groups and high coverage. More frequent treatments resulted in higher incremental costeff ectiveness of all strategies due to decreasing incremental gains (table 4) . Nevertheless, more frequent treatment was highly cost eff ective, including biannual treatment of school-aged children (ICER $347 per DALY averted) and community-wide treatment (ICER $335 per DALY averted) compared with annual treatment (see appendix for community analysis).
The proposed strategy of integrated community-wide treatment was highly cost eff ective compared with A series of one-way sensitivity analyses showed that expansion of treatment from school-aged children to community-wide treatment with 75% coverage would be highly cost eff ective across a range of tested parameters (fi gure 4). The base delivery cost and community delivery cost multiplier were the most important parameters, and were assessed by use of an upper end of $1·50 delivery cost per school-aged child and using a community delivery multiplier of up to ten times the cost of school-based delivery. The ICER was highly robust when varying the schistosomiasis disability weight, treatment frequency, coverage, and relative environmental contribution between preschool-aged children, school-aged children, and adults. The probabilistic sensitivity analysis, which varied many uncertain parameters simultaneously, was also used to assess the eff ect of uncertainty in the model on our main result: community-wide treatment is highly cost eff ective compared with school-aged children alone. This analysis showed study fi ndings were robust with a mean ICER of $219 (95% CI 63-524) per DALY averted (appendix).
Discussion
Our modelling study has shown that integrated community-wide MDA targeting two major helminthiases is a highly cost-eff ective strategy. Great progress has been made in decreasing the burden of helminthiases with use of MDA programmes, but even communities with repeated treatment of school-aged children have been unable to achieve elimination of schistosomiasis and soiltransmitted helminthiasis. 5, 10, 12, 49 Recent models in the past two years have reported the potential benefi ts for expansion of drug coverage to the entire community. 5, 12, 13 The results of our study support these fi ndings and suggest that expanded, community-wide treatment alongside high coverage (>75%) and sustained administration (>5 years) could be crucial in suffi ciently decreasing the community worm load to prevent high reinfection rates and make elimination a possibility in many communities. Importantly, we noted that community-wide treatment would be highly cost eff ective even if elimination could not be achieved, due to substantial disability averted in preschool-aged children, school-aged children, and adults. As a result, MDA will avert much disability and be highly cost eff ective even when prevalence is not substantially reduced. These fi ndings held true across all four communities in Côte d'Ivoire with diff ering prevalence of Schistosoma and soil-transmitted helminth infections. Crucially, treatment of both sets of helminths was highly cost eff ective even in communities with a low prevalence of one of these helminth types, because most costs were spent on treatment delivery and not on the drugs themselves. We also determined that integrated treatment every 6 months could be highly cost eff ective. These fi ndings lend support to the movement towards integrated treatment programmes for schistosomiasis and soiltransmitted helminthiasis, and underscore the need to develop guidelines that address the importance of expanding treatment to include more than only schoolaged children and are based on the local burden of many helminth infections rather than each individually.
If the latest WHO guidelines 6 had been followed (which are specifi c to either schistosomiasis or soil-transmitted helminthiasis), individuals in only one of the four However, because the costs of drugs themselves are low, the infrastructure to deliver MDA-particularly at the community level-accounts for the bulk of total costs. Addition of a second drug to MDA programmes therefore benefi ts from reduced incremental costs, making their use cost eff ective at lower prevalence values than those recommended in non-integrated programmes.
The cost-eff ectiveness of integrated community-wide treatment was robust to local epidemiology and assumptions on cost of treatment, coverage, frequency of treatment, disability measurement, and prevalence of infection. Although the quantitative result (ICER) will vary in other settings as a function of local costs and disease burden, we believe our sensitivity analyses suggest that our main fi nding-that integrated community-wide MDA is highly cost eff ective-will be applicable in many lowresource settings where schistosomiasis and soiltransmitted helminthiasis coexist. The price of community-based delivery was calculated by applying a three-times multiplier to the school-based delivery cost, to account for the increased cost to administer treatment throughout a community. Conservatively high estimates for school-based delivery costs ($0·50) could make the absolute incremental cost between school-based and community-based delivery larger than the three-times multiplier might suggest. Community-wide treatment remained highly cost eff ective across a large range of the community-wide multipliers (1-10 times) and base delivery costs ($0·05-1·50). The 75% coverage used in the main analysis, which is representative of WHO's goal, provided a similar result when compared with present global coverage (15-30%), as shown in the sensitivity analysis.
The latest WHO guidelines suggest treatment of highrisk adults in endemic regions and consideration of community-wide treatment for schistosomiasis in highly endemic communities (>50% prevalence), but this is not usually done in practice. 50 MDA in school-aged children (ICER $118 per DALY averted) and community-wide treatment (ICER $167 per DALY averted) were both highly cost eff ective with similar ICERs, particularly at coverage that exceeded 75%. Treatment of school-aged children and preschool-aged children or adults alone were dominated strategies, meaning that communitywide treatment averted more disability at a lower incremental cost-eff ectiveness. Following an existing treatment framework that focuses on treatment of school-aged children and school-based delivery, one effi cient strategy would be fi rst scaling up to adequate coverage of school-based treatment followed by implementation of community-wide treatment.
Even though the specifi c prevalence threshold that is cost eff ective for inclusion of each age group was not examined explicitly, both school-aged children only and community-wide treatment were deemed highly cost eff ective in all communities ranging from low to highly endemic settings. This result suggests the possibility of lowering prevalence thresholds used in treatment guidelines and the need for cost-eff ectiveness work to inform the specifi c thresholds. In line with previous studies, the use of mean burden (usually estimated by mean eggs per g of faeces) rather than prevalence of infection should also be thought about in creation of these thresholds based on the distribution of disease. 13 The results of this study should be interpreted within the context of the limitations of model parameters and a number of simplifying assumptions. We modelled treatment as an instantaneous reduction in mean burden and increase in haemoglobin; annual treatment was applied simultaneously throughout all communities; perfect mixing was assumed in the subpopulation mean burden; coverage assumed random rather than repeated treatment of individuals within the population; heterogeneity was assumed to be constant throughout the population despite treatment pressure that might concentrate disease burden in a smaller number of hosts; and contributions of animal reservoirs, migration, and socalled superspreaders (highly infectious individuals who transmit their infection to several other people) were not included and could represent important barriers to helminth elimination. We modelled a 15-year period, and assumed constant treatment coverage throughout this period; in reality, treatment acceptance could change over time. Treatment decisions were made on the basis of initial prevalence and were not re-evaluated during the simulation. However, the results show that WHOrecommended treatment (focused on school-aged children only) had little eff ect on prevalence (fi gure 2B) and would be less likely to reduce prevalence substantially enough to change the recommended treatment strategy from WHO.
Treatment costs were not separated into the fi xed component of setting up a programme, and a variable component of increasing treatment frequency or coverage. Helminth disease distribution was modelled with a negative binomial distribution after analysis with primary data and previous models. We did not model disability because of toxic eff ects of therapy, as single dose administration is associated with a very low risk of substantial toxic eff ects in comparison with the extent of disability due to disease. 51 Of the most uncertain parameters is the relative contribution of eggs to the environment from each age group; we assumed that preschool-aged children and school-aged children contributed twice as much in the base case as did adults, and the results were ultimately minimally aff ected across a broad range of assumptions for this parameter.
The disability weight given to schistosomiasis and soiltransmitted helminthiasis has been much debated, and varies greatly depending on the published source used (ie, WHO [Global Burden of Disease 2004], 52 and King and colleagues' meta-analysis 53 ). The disability weight for schistosomiasis varies from 0·005 to 0·15 on a scale from 0 (perfect health) to 1 (death). 21 We ultimately chose a binary disability weight of 0·02, which represents the lowest value of a meta-analysis that examined this disability weight, and assessed the eff ect of this disability weight in sensitivity analyses. 21 The disability structure for soil-transmitted helminthiasis was updated in 2014, and we used these weights. 1 In view of recent controversy about treatment of soil-transmitted helminth infections in the past months, 54, 55 of note is that updated weights for these helminths did not assign any disability for light infections, and did not include any cognitive or educational benefi t from treatment. By contrast, individuals with schistosomiasis received the same disability weight irrespective of infection intensity. Generally, disability weights for these diseases might not truly account for long-term cognitive impairment, which would increase treatment cost-eff ectiveness and could favour treatment of preschool-aged children and school-aged children rather than adults. Although many studies have reported greater prevalence of helminths in school-aged children than in adults, growing scientifi c literature supports our fi nding that adults can often have equivalent or greater disease burden than children, especially for hookworm infections and schistosomiasis. 56, 57 To the best of our knowledge, the empirical data used in our study came from communities that had not received MDA, but there is still a potential undocumented exposure to anthelmintics.
We did not assess treatment of malaria, fi larial infections, strongyloidiasis, or other helminth infections that are often co-endemic in many communities and can be treated concomitantly. Additionally, thought should be given to the role of diff erent helminthiasis control methods-these include water, sanitation, and hygiene, community education, vaccine development, and other measures 58, 59 -which are likely to be important in future elimination eff orts but were not included in this model. Importantly, not every cost-eff ective programme will be aff ordable in all settings and might be subjected to changing funding priorities; however, our fi ndings suggest that expanded community-wide MDA would be cost eff ective while being undertaken, even if the programme was not subsequently maintained. Thus, the goal of this study is to assist in prioritising among the many needed health interventions in low-income settings.
With renewed enthusiasm for control and elimination eff orts targeting helminth infections, questions remain about how to eff ectively deploy resources. Present WHO guidelines, which are based on the individual prevalence of helminth infections and focus on school-aged children alone, are inadequate for informing treatment programmes. Revised guidance is urgently needed to inform the scale-up of treatment programmes worldwide to avert the substantial disability created from soil-transmitted helminthiasis, schistosomiasis, and other neglected tropical diseases.
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